Mark Herring, MD
Neurology · Springfield, ORNPI 1689636284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 58 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 27.3% of the total.
Across 58 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$323
- Novartis$148
- Biogen$102
- Johnson & Johnson$77
- Neurocrine Biosciences, Inc.$43
- Lundbeck LLC$39
- plus $451 from 21 others
Across 3 payments — averaging $1235.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4K
What the payments were for
- Speaking & faculty fees$202%
- Food & beverage$1,08792%
- Education$777%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $323 |
| Novartis | 8 | $148 |
| Biogen | 6 | $102 |
| Johnson & Johnson | 1 | $77 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Lundbeck LLC | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Advanced Respiratory, Inc | 1 | $36 |
| EMD Serono, Inc. | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Nalu Medical, Inc. | 1 | $25 |
| Greenwich Biosciences, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $20 |
| Pfizer | 1 | $20 |
| Sarepta Therapeutics, Inc. | 1 | $20 |
| Immedica Pharma US, Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $18 |
| UCB, Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Adamas Pharmaceuticals, Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$1,184 in reported general payments places this provider in the 60th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GilenyaFingolimod Hcl | 12 | $125,539 |
| FingolimodFingolimod Hcl | 30 | $74,193 |
| Nurtec OdtRimegepant Sulfate | 23 | $40,796 |
| AptiomEslicarbazepine Acetate | 12 | $17,387 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $13,183 |
| Gabapentin | 230 | $4,350 |
| Lacosamide | 30 | $4,154 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 66 | $3,388 |
| Levetiracetam | 55 | $3,348 |
| Eletriptan HbrEletriptan Hydrobromide | 33 | $2,801 |
| Baclofen | 59 | $2,166 |
| Memantine Hcl | 80 | $1,593 |
| Primidone | 30 | $1,252 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $1,091 |
| Clonazepam | 141 | $1,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisGilenya | $148 | $125,53912 claims |
| PfizerNurtec Odt | $20 | $40,79623 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $38 | $17,38712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 228 neurology providers in Oregon.
Other neurology in Springfield
- David ClarkSpringfield$1.1M
- Laura QiSpringfield$5K
- Sara BatyaSpringfield$3K
- Derek McFaulSpringfield$3K
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Walter CarliniMedford$425K
- Herbert KrobPortland$416K
- Stanley CohanPortland$334K
- Matthew BrodskyPortland$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.